6 Results for "

protected peptide intermediates

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "protected peptide intermediates" in MCE Product Catalog:

Cat. No.: HY-W072147
CAS No.: 82911-78-2
Synonyms: Fmoc-L-Ser-OMe
Research Areas:  

Others

Fmoc-Ser-OMe (Fmoc-L-Ser-OMe) is an Fmoc-protected L-serine methyl ester and also a solid-phase peptide synthesis intermediate. Fmoc-Ser-OMe is linked to Ellman resin via its hydroxyl side chain. Fmoc-Ser-OMe is used in peptide synthesis .
loading...
    loading...
Cat. No.: HY-W048682
CAS No.: 202920-22-7
Research Areas:  

Others

Fmoc-1-methyl-L-histidine is an Fmoc-protected amino acid as well as an amino acid-containing building block. Fmoc-1-methyl-L-histidine is applicable to the generation of the ε-nitrogen-coordinated copper center in nitrite copper reductase. It also serves as an intermediate in peptide synthesis .
loading...
    loading...
Cat. No.: HY-W008024
CAS No.: 125238-99-5
Research Areas:  

Others

Fmoc-Dab(Boc)-OH (Compound 5) is an amino acid derivative with an Fmoc protecting group, which can be used to synthesize agents that inhibit neointimal formation induced by rat balloon injury. Fmoc-Dab(Boc)-OH serves as an intermediate for the synthesis of bioactive peptides or their analogs .
loading...
    loading...
Cat. No.: HY-129361
CAS No.: 1834516-06-1
Research Areas:  

Cancer

Fmoc-Ala-Ala-Asn-PABC-PNP is a peptide-based linker intermediate composed of Fmoc-protected Ala-Ala-Asn, PABC, and PNP. Fmoc-Ala-Ala-Asn-PABC-PNP can be used to prepare Auristatin antibody-drug conjugates (ADCs). Fmoc-Ala-Ala-Asn-PABC-PNP is applicable to tumor-related research .
loading...
    loading...
Cat. No.: HY-W574398
CAS No.: 172405-45-7
Research Areas:  

Others

Fmoc-Aeg-OH is a peptide nucleic acid (PNA) backbone intermediate and an Fmoc-protected carboxylic acid. Fmoc-Aeg-OH can be coupled with base acetic acids to synthesize Fmoc-protected PNA monomers, including those with modified bases .
loading...
    loading...
Cat. No.: HY-P12216
CAS No.: 3115127-25-5
Target:  

Drug Intermediate

Research Areas:  

Metabolic Disease

Enlicitide northern fragment 4 is a key intermediate obtained via the retrosynthetic disconnection of Enlicitide decanoate (HY-W1126955). Enlicitide northern fragment 4 participates in the protecting-group-free biocatalytic convergent assembly of Enlicitide decanoate, an oral macrocyclic peptide PCSK9 inhibitor. Enlicitide northern fragment 4 can be used for the synthesis of Enlicitide decanoate, thereby supporting research related to hypercholesterolemia .
loading...
    loading...